You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Both organizations plan to contribute their respective areas of expertise to work on two research projects to improve patient treatment options and outcomes.
Researchers screened cancer cell lines to detect mutations and drug combinations that might sensitize tumors to drugs that impair anti-apoptosis proteins.
A proteomic analysis of pancreatic ductal adenocarcinoma tumor and stromal samples led to a stromal protein that appears to coincide with tumor aggressiveness.
Researchers saw abbreviated overall survival times in estrogen receptor-positive metastatic breast cancer patients with ESR1 mutations in their cell-free DNA.
Researchers used genomic approaches to search for disease clues in purified cells from ileum or colon biopsies of pediatric inflammatory bowel disease patients.
Olink Proteomics will focus on developing protein biomarker discovery products while Olink Bioscience will work on other technologies arising from its IP portfolio.
The partners plan to develop a computational platform that automates pipelines and processes for biomarker discovery, drug recovery and repositioning, and more.
Under the partnership, the University of Miami will provide samples and Berg will analyze them using its Interrogative Biology platform.
The certification covers the development, production, and distribution of in vitro diagnostics for autoimmune disease.
The company's platform mines multiple omics datasets to provide a complete picture of the genes and pathways affected in disease, drug response, more.
Researchers have developed a robotic lab assistant, the Verge reports.
CBC News reports Canada's Supreme Court is to rule on the constitutionality of the country's genetic non-discrimination law today.
The Associated Press reports the World Health Organization is sending experts to China to investigate the animal source of SARS-CoV-2.
In Science this week: atlas of affected cell populations in idiopathic pulmonary fibrosis, and more.